免疫疗法在早期和转移性非小细胞肺癌中的作用

Attila Lieber, Attila Makai, Zsuzsanna Orosz, Tamás Kardos, Susil Joe Isaac, Ilona Tornyi, Nóra Bittner
{"title":"免疫疗法在早期和转移性非小细胞肺癌中的作用","authors":"Attila Lieber, Attila Makai, Zsuzsanna Orosz, Tamás Kardos, Susil Joe Isaac, Ilona Tornyi, Nóra Bittner","doi":"10.3389/pore.2024.1611713","DOIUrl":null,"url":null,"abstract":"In the past decade we have seen new advances and thus remarkable progress in the therapeutic options for non-small cell lung cancer (NSCLC). Among cytostatic therapies with new approaches in molecularly targeted therapies, we see new developments in a wide range of applications for immunotherapies. In this review we discuss the new potential modalities for the use of immune checkpoint inhibitors (ICIs) in the frontlines, including in early-stage (perioperative) and metastatic settings. The perioperative use of ICIs in both neoadjuvant and adjuvant settings may show benefits for patients. In early-stage NSCLC (from stage IIB and above) a multimodality approach is recommended as the gold standard for the treatment. After surgical resection platinum-based adjuvant chemotherapy has been the standard of care for many years. Based on the benefit of disease-free survival, the approval of adjuvant atezolizumab and adjuvant pembrolizumab was a significant breakthrough. In the metastatic setting, the use of immune checkpoint inhibitors with chemotherapy, regardless of PD-L1 expression or ICI alone (PD-L1 expression equal to or greater than 50%) also improves overall survival and progression-free survival.","PeriodicalId":20037,"journal":{"name":"Pathology and Oncology Research","volume":" 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of immunotherapy in early-stage and metastatic NSCLC\",\"authors\":\"Attila Lieber, Attila Makai, Zsuzsanna Orosz, Tamás Kardos, Susil Joe Isaac, Ilona Tornyi, Nóra Bittner\",\"doi\":\"10.3389/pore.2024.1611713\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the past decade we have seen new advances and thus remarkable progress in the therapeutic options for non-small cell lung cancer (NSCLC). Among cytostatic therapies with new approaches in molecularly targeted therapies, we see new developments in a wide range of applications for immunotherapies. In this review we discuss the new potential modalities for the use of immune checkpoint inhibitors (ICIs) in the frontlines, including in early-stage (perioperative) and metastatic settings. The perioperative use of ICIs in both neoadjuvant and adjuvant settings may show benefits for patients. In early-stage NSCLC (from stage IIB and above) a multimodality approach is recommended as the gold standard for the treatment. After surgical resection platinum-based adjuvant chemotherapy has been the standard of care for many years. Based on the benefit of disease-free survival, the approval of adjuvant atezolizumab and adjuvant pembrolizumab was a significant breakthrough. In the metastatic setting, the use of immune checkpoint inhibitors with chemotherapy, regardless of PD-L1 expression or ICI alone (PD-L1 expression equal to or greater than 50%) also improves overall survival and progression-free survival.\",\"PeriodicalId\":20037,\"journal\":{\"name\":\"Pathology and Oncology Research\",\"volume\":\" 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology and Oncology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/pore.2024.1611713\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology and Oncology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/pore.2024.1611713","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在过去的十年中,我们看到了非小细胞肺癌(NSCLC)治疗方案的新进展,从而取得了显著进步。在细胞抑制疗法和分子靶向疗法的新方法中,我们看到了免疫疗法广泛应用的新进展。在这篇综述中,我们将讨论免疫检查点抑制剂(ICIs)在前线(包括早期(围手术期)和转移期)使用的新的潜在模式。在新辅助治疗和辅助治疗中,围手术期使用 ICIs 可为患者带来益处。对于早期 NSCLC(IIB 期及以上)患者,建议将多模式疗法作为治疗的金标准。多年来,手术切除后的铂类辅助化疗一直是治疗的标准。基于无病生存期的优势,辅助治疗阿特珠单抗和辅助治疗彭博利珠单抗的批准是一项重大突破。在转移性环境中,免疫检查点抑制剂与化疗联合使用,不论PD-L1表达或单用ICI(PD-L1表达等于或大于50%),也能改善总生存期和无进展生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The role of immunotherapy in early-stage and metastatic NSCLC
In the past decade we have seen new advances and thus remarkable progress in the therapeutic options for non-small cell lung cancer (NSCLC). Among cytostatic therapies with new approaches in molecularly targeted therapies, we see new developments in a wide range of applications for immunotherapies. In this review we discuss the new potential modalities for the use of immune checkpoint inhibitors (ICIs) in the frontlines, including in early-stage (perioperative) and metastatic settings. The perioperative use of ICIs in both neoadjuvant and adjuvant settings may show benefits for patients. In early-stage NSCLC (from stage IIB and above) a multimodality approach is recommended as the gold standard for the treatment. After surgical resection platinum-based adjuvant chemotherapy has been the standard of care for many years. Based on the benefit of disease-free survival, the approval of adjuvant atezolizumab and adjuvant pembrolizumab was a significant breakthrough. In the metastatic setting, the use of immune checkpoint inhibitors with chemotherapy, regardless of PD-L1 expression or ICI alone (PD-L1 expression equal to or greater than 50%) also improves overall survival and progression-free survival.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信